qualitative research grounded in SEC filings & market-flow signals Quant side · QuantOrb.pro ↗

RVTY — Tear Sheet

REVVITY, INC.

covers US session 2026-10-23 · Tear sheet created 21 days ago

AdCho Opinion

Underweight

Bottom Line

Underweight: a stretched multiple against falling GAAP earnings and a tape that fails to confirm its highs — fading MACD, repeated supply-zone rejections — while an intact uptrend and a genuine cash-flow inflection argue against a full exit.

Market Sentiment Summary

The run's own verdict reads Mildly Bullish at 6.1 out of 10 with low confidence. Coverage is thin.

RVTY daily chart

sessions

Loading chart…

How to read this chart
  1. Top: price candles (green up, red down) with Bollinger Bands (20, 2) in dashed orange, the 50-session average in blue, the 200-session average in dashed orange, and volume bars along the bottom
  2. Middle: RSI (14), Wilder’s method, with dashed guides at 30 and 70
  3. Bottom: MACD (12, 26, 9): MACD line, dashed signal line and a green/red histogram

Prices: Yahoo Finance daily bars, split- and dividend-adjusted; indicators computed on two years of history, then the window is cut · as of latest session · Chart by TradingView Lightweight Charts™ © TradingView, Inc.

Share this tear sheet

X Facebook LinkedIn Reddit WhatsApp Email

Executive Summary

  • We read RVTY as an Underweight, a staged trim, because the bear case carried the decisive issues at this price
  • The decisive counterweight is valuation: a rich trailing multiple against modest revenue compounding and GAAP net income falling three periods running
  • Cash conversion reads largely as an amortization echo of the earlier acquisition spree, with capital spending at the low end of its recent history
  • The tape refuses to confirm the highs: a thin-volume record close, fading MACD against price, and repeated rejection of the supply zone
  • The constructive leg is real: an intact rising trend stack, a genuine free-cash-flow inflection, and sector leadership the screens independently confirm
  • The balance rests on event geometry: capped upside into an unquantified earnings print against deeper air toward the moving-average supports
  • We hold a hedged residual where the options desk cooperates and let the pre-committed post-print branches arbitrate

Market Sentiment

  • We read the sentiment verdict as mildly bullish with low confidence, and we hold that restraint as stated
  • The tape signal is genuinely split: momentum screens flash strength while money flow and passive flows refuse to confirm
  • Independent technical voices across platforms converge on a Stage-2 uptrend printing new highs inside the strongest sector
  • The news lane was event-light and marketing-led: a product launch doubled across wires, screening pieces, and peer previews, nothing disclosure-driven
  • Coverage gaps are real — promo solicitations crowd the social feed, one platform's sample is far below any reliability threshold, event odds stayed silent
  • We weight the sentiment leg light against the documentary valuation and flow evidence — direction is broadly bullish, confirmation is missing

News

get_news

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

The originating announcement of the Signals LabGistics launch, doubled by syndicated coverage in the same window.

AdCho insight: Double coverage marks a scheduled, verified product event rather than chatter — the one concrete company-side anchor this week for the lab-workflow theme, weighted light by the sheet against its flow and valuation caveats.

get_news

Revvity Launches Signals LabGistics to Coordinate Scientific Workflows

Syndicated coverage of Revvity's launch of a solution that connects and orchestrates scientific workflows, extending the Signals informatics platform.

AdCho insight: On-strategy product execution supporting the recurring-software mix — a genuine positive the sheet still treats as modest against its valuation and flow objections.

get_news

ELV vs. RVTY: Which Stock Is the Better Value Option?

A cross-industry value screen pairing Revvity against Elevance Health; the headline carries no verdict.

AdCho insight: Relative-value attention frames Revvity among depressed health-care large caps, which supports visibility but adds no directional evidence for either side of the sheet's trim.

get_news

Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings

A preview positioning IDEXX Laboratories ahead of its quarterly report within the diagnostics and lab-tools complex.

AdCho insight: Peer prints land before Revvity's own unquantified results, so IDEXX's volumes and spending commentary are the nearest read-through to the end markets behind the sheet's cash-quality debate.

get_news

Labcorp Prepares to Report Q3 Earnings: What's in the Cards?

A preview of Labcorp's quarterly results, the lab-services peer reporting ahead of Revvity.

AdCho insight: The most direct read-through on diagnostics volumes and academic and biopharma spending ahead of the event risk the sheet's geometry case centers on.

get_news

Align Technology to Report Q3 Earnings: What's in the Cards?

A preview of Align Technology's quarterly report inside a broad health-care devices earnings week.

AdCho insight: Added catalyst density in the same reporting window, with peer results arriving ahead of Revvity's own print and priming sector tone.

get_global_news

Stock market today: Dow sinks 600 points, S&P 500, Nasdaq drop to cap a volatile week, oil prices rise

The week's featured session: a sharp broad-equity selloff with the Dow down heavily, the S&P 500 and Nasdaq lower, and oil rising — a risk-off close to a volatile week.

AdCho insight: Broad risk appetite deteriorated straight into Revvity's earnings window, thickening the air around a richly valued long-duration name the sheet already declines to chase.

get_global_news

Dow and Small Caps Climb Weekly While Nasdaq Slips on Megacap Earnings Charges

The weekly rotation picture: Dow and small caps finished higher while the Nasdaq slipped under megacap earnings charges.

AdCho insight: Money rotated away from long-duration growth — the cohort a high-multiple tools name occupies — a cross-current the sheet's de-rating caution sits directly in.

Social

pauldgilson

$RVTY one on my watchlist, building higher lows under $158.00. Life Sciences Tools & Services sub-sector. ATR - 3.7% Avg. dollar Vol 20d - $284M Earnings in 11 days Good volume since mid-August when it broke above the VWAP from the all time high in 2022. Will watch today https://t.co/bgZrCxLJYs

2026-10-23

AdCho insight: The most granular retail-technical read in the capture: higher lows building under the $158 area, a mid-August VWAP breakout on good volume, and an earnings marker roughly eleven days out — momentum evidence the sheet credits, framed by its author as a watch item rather than a position.

matt_bern8

2/4 — BIOTECH & HEALTHCARE 🧬 This is where I look for catalysts that don’t depend on AI sentiment. My 5 names: $REGN — commercial scale + pipeline $VRTX — specialty medicines + new product opportunities $ALNY — RNAi platform + product growth $RVTY — life-sciences tools

2026-10-23

AdCho insight: A rotation rationale placing Revvity inside the healthcare cohort sought for catalysts independent of AI sentiment — a demand-side argument for the space that sits alongside the sheet's stance without answering its valuation-and-flow objections.

WealthBranch

Shape twins of $AAPL (Apple): $SPNT $IBEX $RVTY. We scan 5,475 charts every day. 197 additional trade setups inside the app. Link in profile. https://t.co/PflqsDwn6O

2026-10-23

AdCho insight: Promotional pattern-screen content — the Apple shape-twin comparison carries little informational weight, but it is itself evidence of the retail crowding the sheet flags around the tape.

Polymarket

Will Tatyana Ali be eliminated in week 7 of Dancing With The Stars: Season 35?
Yes 33% ($3,862 volume, resolves 2026-10-28)

Will Connor Wood be eliminated in week 7 of Dancing With The Stars: Season 35?
Yes 26% ($3,694 volume, resolves 2026-10-28)

Will Julia Stiles be eliminated in week 7 of Dancing With The Stars: Season 35?
Yes 7% ($2,533 volume, resolves 2026-10-28)

Will Harry Shum Jr. be eliminated in week 7 of Dancing With The Stars: Season 35?
Yes 39% ($1,744 volume, resolves 2026-10-28)

Will Jenna Dewan be eliminated in week 7 of Dancing With The Stars: Season 35?
Yes 8% ($1,534 volume, resolves 2026-10-28)

Will Jackson Olson be eliminated in week 7 of Dancing With The Stars: Season 35?
Yes 73% ($511 volume, resolves 2026-10-28)

Live odds at run time (UTC) — not the covered session's odds; market-level context, not signals to act on. Topic: “Revvity Inc”.

Management Sentiment & Catalyst Highlights

  • Management's own voice was quiet this window: no fresh results disclosure landed, so tone and guidance posture stay unreadable from company language
  • The company did announce the Signals LabGistics launch, extending its informatics platform toward connecting and orchestrating scientific workflows
  • Its standing self-description is a health-science solutions provider spanning discovery to development and diagnosis to cure, marketed worldwide
  • The launch maps onto that story and onto the recurring-software mix the plan's cash-quality discussion wants to see scale
  • The balance-sheet repair stands as the quiet capital story: liabilities cut sharply and cash rebuilt, cushioning every scenario short of a demand shock
  • Catalysts sit ahead, not behind: an unquantified quarterly print with nothing yet disclosed, preceded by peer diagnostics prints as read-throughs
  • Rates are the visible macro lever: the ten-year yield eased back below five percent, relief for a long-duration multiple

Key Risk Factors

  • The primary risk is momentum failing into the print: a lower-high RSI and fading MACD against price making new highs
  • The supply zone has rejected buyers repeatedly, most ominously on the heaviest volume, capping upside while leaving deeper air below
  • Growth quality is the second leg: a rich multiple carried by modest compounding, with EPS growth that is buyback arithmetic
  • Rates cut both ways: long-end relief arrived, but sticky inflation has stalled the easing path long-duration names need
  • The hedge itself is conditional — if the options desk does not cooperate, the residual rides the print unprotected
  • Evidence quality caps conviction: a thin, months-stale institutional snapshot, absent event odds, and promo crowding inflating the bullish chorus
  • Counterweight to every bear leg: the trend stack is intact and the cash inflection is genuine, so this stays a trim, not a verdict

QuantOrb.pro Quantitative Signals

MFI (14-day)

54.06

neutral zone · None screen

qOp signal strength

NONE · 35%

quantitative screen, not a recommendation

Money-flow and momentum readings from this run's own engine outputs (QuantOrb snapshot as cited in Sources; technicals as of the covered session) — context, not signals to act on.

Not a recommendation. A quantitative screen, not a recommendation — the 13F data are a non-exhaustive quarter-end snapshot subject to a reporting lag of up to 45 days.

qOp quant view →

Sources

Facts (verifiable): SEC filings via the QuantOrb document corpus · QuantOrb money-flow & 13F datasets. Reading (AI-powered): AdCho’s synthesis via a multi-analyst AI engine.

Sheet schema adcho.tearsheet.v1 · rendered by AdCho · freshness day 21 (D11 day-0 rule, US-session dates only)